In vitro anticoagulation monitoring of low-molecular-weight heparin

Chinese Medical Journal

Volumn 122, Issue 10, 2009, Pages 1199-1202

  Wang, Jian Qi ^a   Shi, Xu Bo ^a   Yang, Jin Gang ^b   Hu, Da Yi ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b FUWAI HOSPITAL   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Activated clotting time; Anti Xa factor; Anticoagulation monitoring; Low molecular weight heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; COAGULATING AGENT; DALTEPARIN; ENOXAPARIN; GLASS; INFUSORIAL EARTH; KAOLIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PROTHROMBIN A;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MONITORING; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MAGNET; MALE; NORMAL HUMAN; PROTEIN FUNCTION; VENOUS BLOOD;

ADULT; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; COAGULANTS; FEMALE; GLASS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KAOLIN; MALE; MIDDLE AGED; NADROPARIN;

EID: 68249151987     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.10.016     Document Type: Article

References (13)

1. Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes. J Thromb Haemost 2004; 2: 547-550.
2. Bounameaux H, de Moerloose P. Is laboratory monitoring of low molecular-weight heparin therapy necessary? No. J Thromb Haemost 2004; 2: 551-554.
3. Milovic NM, Behr JR, Godin M, Hou CS, Payer KR, Chandrasekaran A, et al. Monitoring of heparin and its low-molecular-weight analogs by silicon field effect. Proc Natl Acad Sci U S A 2006; 103: 13374-13379.
4. Middeldorp S. Heparin: from animal organ extract to designer drug. Thromb Res 2008; 122: 753-762.
5. Clem JR. Anti-factor Xa levels: when should they be used? S D Med 2006; 59: 261-262.
6. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45-54.
7. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 2006; 52: 1042-1050.
8. Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004; 292: 55-64.
9. Lepor NE. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors. Rev Cardiovasc Med 2007; 8 Suppl 3: S9-S17.
10. Cavusoglu E, Lakhani M, Marmur JD. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration. J Invasive Cardiol 2005; 17: 416-421.
11. British Committee for Standards in Haematology. Guidelines on the use and monitoring of heparin. Br J Haematol 2006; 133: 19-34.
12. Jack Hirsh, Robert Raschke. Heparin and low-molecular-weight heparin. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 188S-203S.
13. Ostadal P, Alan D, Vejvoda J, Segethova J, Kruger A. Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome. Exp Clin Cardiol 2008; 13: 175-178.